Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Commercial Companies Deals

Merck & Co Could Be Plotting $30bn Bid For Seagen

Regulatory Concerns Remain

  • News

Executive Summary

A buyout of Seagen would boost Merck & Co’s goal of becoming the dominant player in oncology by 2025, but the deal is said to be far from done.

You may also be interested in...



Seagen CEO Search Under Way As Longtime Leader Siegall Resigns In Scandal

Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.

Twice As Nice: Seattle Genetics, Merck & Co. Partner On Two Cancer Drugs

Merck & Co. will pay Seattle Genetics $725m up front in cash under the two deals and make a $1bn equity investment in the company, providing financial flexibility to broadly fund the pipeline.

Encouraging Biomarker Data Lift UniQure’s Huntington’s Disease Hopes

Hopes rise as first four evaluable patients experienced no serious adverse events, and a sustained decline in level of key Huntington’s disease protein with the novel gene therapy product.

Table

View full table

Topics

Related Companies

Tags:
Commercial Companies Deals
Latest News

BioMarin Rolls Up Sleeves To Prepare For Roctavian’s EU Debut

Sarepta’s Exondys 51 Successor On Clinical Hold, But Quick Resolution Expected

Asia Deal Watch: invoX Builds Novel Pipeline Through $161m F-star Acquisition

Encouraging Biomarker Data Lift UniQure’s Huntington’s Disease Hopes

UsernamePublicRestriction

Register

SC146578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By